LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Kings Path Partners LLC

Kings Path Partners LLC reduced its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.5% during the 4th quarter, Holdings Channel reports. The firm owned 17,733 shares of the medical instruments supplier’s stock after selling 275 shares during the quarter. LeMaitre Vascular makes up about 0.7% of Kings Path Partners LLC’s holdings, making the stock its 26th largest holding. Kings Path Partners LLC’s holdings in LeMaitre Vascular were worth $1,634,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in LMAT. NBC Securities Inc. lifted its stake in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares in the last quarter. USA Financial Formulas purchased a new position in shares of LeMaitre Vascular in the third quarter valued at approximately $60,000. GAMMA Investing LLC boosted its stake in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the last quarter. Van ECK Associates Corp purchased a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $75,000. Finally, Canada Pension Plan Investment Board acquired a new position in LeMaitre Vascular in the 2nd quarter valued at $82,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $1.04 during midday trading on Monday, reaching $92.78. 36,704 shares of the stock were exchanged, compared to its average volume of 147,981. The stock has a market capitalization of $2.09 billion, a P/E ratio of 50.70, a PEG ratio of 2.47 and a beta of 0.96. The company has a 50 day simple moving average of $98.44 and a 200 day simple moving average of $90.91. LeMaitre Vascular, Inc. has a twelve month low of $54.03 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter last year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a $0.16 dividend. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.69%. LeMaitre Vascular’s payout ratio is currently 34.97%.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.